Warning Letter — Medline Inc
The FDA issued a Warning Letter to Medline Inc. on May 28, 2026, following an evaluation by the Center for Drug Evaluation and Research (CDER).
Medline Inc., specifically its drug manufacturing or distribution operations, and associated quality and compliance departments.
An enforcement action by CDER signifies identified deviations from drug-related regulations or safety standards. This suggests potential deficiencies in manufacturing processes or quality oversight that may require significant remediation efforts to satisfy FDA requirements and avoid further regulatory escalation.
Regulatory and QA teams should conduct a thorough audit of manufacturing facilities and quality systems to ensure alignment with CDER-enforced drug standards. Documentation practices and compliance with current Good Manufacturing Practice (cGMP) should be verified against recent inspection findings.
FDA Warning Letter issued to: Medline Inc. 05/28/2026 — Center for Drug Evaluation and Research (CDER). Source: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/medline-inc-724347-05282026
Open in openFDA / FDA.gov